Lenses, systems and methods for providing binocular customized treatments to correct presbyopia

Information

  • Patent Grant
  • 11389329
  • Patent Number
    11,389,329
  • Date Filed
    Friday, May 15, 2020
    4 years ago
  • Date Issued
    Tuesday, July 19, 2022
    2 years ago
Abstract
An apparatus, such as lenses, a system and a method for providing custom ocular aberrations that provide higher visual acuity. The apparatus, system and method include inducing rotationally symmetric aberrations along with an add power in one eye and inducing non-rotationally symmetric aberrations along with an add power in the other eye to provide improved visual acuity at an intermediate distance.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

This invention relates generally to correction of eye defects, and more specifically, to a system, method and apparatus for providing binocular customized treatments for remedying presbyopia.


Description of the Related Art

Surgery on the human eye has become commonplace in recent years. Many patients pursue eye surgery as an elective procedure to treat an adverse eye condition, such as to avoid the use of contact lenses or glasses. One eye condition that can be treated surgically is presbyopia. A patient suffering from presbyopia lacks the capability of the eye lens to accommodate or bend and thus to see at far distance and at near distance. Presbyopia can be induced by age and/or pseudophakia (a condition in which a natural lens has been replaced with an intraocular lens).


Several treatment options are available for presbyopia. For example, multifocal intraocular lenses, extended depth of focus lenses, corneal inlays or other accommodating intraocular lenses can be surgically implanted in the eye of a patient suffering from presbyopia to allow the patient to focus and refocus between near and far objects. Another treatment option available to patients suffering from presbyopia is based on monovision. In this option, generally the dominant eye is targeted for distant vision and the non-dominant eye is targeted for near vision. This can be achieved by implanting the dominant eye with an intraocular lens (IOL) having a power that achieves plano refraction such that the dominant eye has no refractive error and by implanting the non-dominant eye with an IOL that has an add power between 1.0-2.0 Diopter over the dominant eye.


However, such an approach can result in sub-optimal intermediate vision if the non-dominant eye is targeted for near vision or sub-optimal near vision if the non-dominant eye is targeted for intermediate vision. Additionally, some patients may not tolerate the refractive differences in the dominant and non-dominant eye.


SUMMARY OF THE INVENTION

Multifocal intraocular lenses (IOLs) providing two or more optical powers, for example, one for near vision and one for distant vision, can be implanted in the eye of a patient suffering from presbyopia to overcome some of the disadvantages of monovision. Although multifocal IOLs can lead to improved quality of vision for many patients, some patients can experience undesirable visual effects (dysphotopsia), e.g. glare or halos. For example, if light from a distant point source is imaged onto the retina by the distant focus of a multifocal IOL, the near focus of the multifocal IOL will simultaneously superimpose a defocused image on top of the image formed by the distant focus. This defocused image may manifest itself in the form of a ring of light surrounding the in-focus image, and is referred to as a halo. Rotationally symmetric multifocal designs present symmetric halo shapes, while non-rotationally symmetric multifocal lenses present asymmetric halos. Additionally, intermediate vision may be compromised in multifocal IOLs that are configured to provide near and distant vision.


Thus, there exists a need for an ophthalmic solution that provides improved vision at all of near, far and intermediate distances while reducing dysphotopsia. One approach to provide improved vision at all of near, far and intermediate distances while reducing dysphotopsia can be a lens with an extended depth of focus. Without subscribing to any particular, a lens with an extended depth of focus can image objects with a certain distance of its focal point with acceptable sharpness on the retina. Thus, an extended depth of focus lens can produce images with acceptable sharpness for objects located at intermediate to far distances or for objects located at near to intermediate distances. Various techniques for extending the depth of focus of a lens have been proposed. For example, some approaches are based on intraocular lenses with refractive or diffractive zones with different powers.


The embodiments disclosed herein include various ophthalmic lens solutions (such as, for example, contact lenses, IOLs, phakic IOLs, corneal inlays, as well as corneal reshaping procedures such as, laser treatments, or combinations of thereof etc.) for treating ophthalmic conditions in both eyes to enhance visual acuity at near, intermediate and far distances, and therefore provide a full range of vision. In various embodiments disclosed herein, binocular extension of depth of focus is achieved by inducing rotationally symmetric aberrations (e.g. fourth and/or higher order spherical aberrations) in one eye and by inducing non-rotationally symmetric aberrations (e.g. astigmatism, coma and/or trefoil) in the other eye to enhance visual acuity at an intermediate distance. In another aspect, binocular extension of depth of focus is achieved by a rotationally symmetric diffractive lens solution in one eye and a rotationally asymmetric diffractive lens solution in the other eye. In another aspect, binocular extension of depth of focus is achieved by a rotationally symmetric refractive lens solution in one eye and a rotationally asymmetric refractive lens solution in the other eye. In another aspect, visual acuity at an intermediate distance can be enhanced by applying scaled version of natural aberrations that are present in the patient's eye, as referred in U.S. patent application Ser. No. 13/690,505 filed on Nov. 30, 2012 and entitled Lenses, Systems and Methods For Providing Custom Aberration Treatments And Monovision To Correct Presbyopia which is incorporated herein by reference, in addition to inducing rotationally symmetric and asymmetric aberrations. In an alternative embodiment, the aberration patterns (e.g. fourth and/or higher order spherical aberrations and astigmatism, coma and/or trefoil) may also be imposed on the top of monovision, achieved with either refractive or diffractive techniques or on the top of a mix and match of multifocal or extended depth of focus lenses, which may also combine symmetric and asymmetric concepts binocularly.


In various embodiments, a binocular vision simulator can be used to determine the amount and type of aberrations to be induced in each eye. The combination that provides the best through focus performance as well as the patient's comfort is chosen. An example method of implementing the concepts discussed herein includes: (i) determining with a binocular vision simulator a first amount of rotationally symmetric or non-rotationally symmetric aberration which provides visual acuity for intermediate and distant vision in a first eye; (ii) determining with the binocular vision simulator a second amount of rotationally symmetric or non-rotationally symmetric aberration which provides visual acuity for intermediate and near vision in a second eye; (iii) applying the first amount of rotationally symmetric or non-rotationally symmetric aberration in the first eye; and (iv) applying the second amount of non-rotationally symmetric or rotationally symmetric aberration in the second eye, wherein a rotationally symmetric aberration pattern is applied to the second eye if a non-rotationally symmetric aberration pattern is applied to the first eye and vice-versa. Binocular visual acuity or just visual perception at different defocus position may be tested in those conditions. The test may also be performed in the presence of rotationally symmetric and asymmetric diffractive profiles once applied using the binocular visual simulator, with a goal of determining the combination of aberrations and diffractive ophthalmic solutions which provide a continuous range of vision.


Various embodiments disclosed herein include lenses, methods and systems that can correct presbyopia by extending the depth of focus for lenses that are configured to provide distant or near vision such that improved intermediate vision is provided by binocular summation.





BRIEF DESCRIPTION OF THE DRAWINGS

Understanding of the present invention will be facilitated by consideration of the following detailed description of the preferred embodiments of the present invention taken in conjunction with the accompanying drawings, in which like numerals refer to like parts, and in which:



FIG. 1 is a diagram illustrating the relevant structures and distances of the human eye.



FIGS. 2A and 2B are flowcharts of an implementation of a method used to determine the combination of aberrations that can be induced to provide vision acuity at near, far and intermediate distances.



FIG. 3 is a diagram illustrating aspects of a system that can be used to implement the method described in FIG. 2.


FIG. 4A1-4A5 shows various embodiments of lenses having rotationally asymmetric diffractive features.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

It is to be understood that the figures and descriptions of the present invention have been simplified to illustrate elements that are relevant for a clear understanding of the present invention, while eliminating, for the purpose of clarity, many other elements found in typical lenses, lens systems and lens design methods. Those of ordinary skill in the arts can recognize that other elements and/or steps are desirable and may be used in implementing the embodiments described herein.


The embodiments described herein are directed to an ophthalmic lens, such as an intraocular lens (IOL), or a corneal implant, and other vision correction methodologies, such as laser treatments, and a system and method relating to same, for providing rotationally symmetric aberration patterns in one eye and non-rotationally symmetric aberration patterns in the other eye in order to induce a binocular customized treatment that achieves visual acuity at a range of distances.


The terms “power” or “optical power” are used herein to indicate the ability of a lens, an optic, an optical surface, or at least a portion of an optical surface, to redirect incident light for the purpose of forming a real or virtual focal point. Optical power may result from reflection, refraction, diffraction, or some combination thereof and is generally expressed in units of Diopters. One of ordinary skill in the art will appreciate that the optical power of a surface, lens, or optic is generally equal to the reciprocal of the focal length of the surface, lens, or optic, when the focal length is expressed in units of meters.



FIG. 1 is a schematic drawing of a human eye 200. Light enters the eye from the left of FIG. 1, and passes through the cornea 210, the anterior chamber 220, a pupil defined by the iris 230, and enters lens 240. After passing through the lens 240, light passes through the vitreous chamber 250, and strikes the retina 260, which detects the light and converts it to a signal transmitted through the optic nerve to the brain (not shown). Cornea 210 has corneal thickness (CT), which is the distance between the anterior and posterior surfaces of the center of the cornea 210. Anterior chamber 220 has an anterior chamber depth (ACD), which is the distance between the posterior surface of the cornea 210 and the anterior surface of the lens 240. Lens 240 has lens thickness (LT) which is the distance between the anterior and posterior surfaces of the lens 240. The eye has an axial length (AXL) which is the distance between the center of the anterior surface of the cornea 210 and the fovea of the retina 260, where the image is focused.


The anterior chamber 220 is filled with aqueous humor, and optically communicates through the lens 240 with the vitreous chamber 250. The vitreous chamber 250 is filled with vitreous humor and occupies the largest volume in the eye. The average adult eye has an ACD of about 3.15 mm, although the ACD typically shallows by about 0.01 mm per year. Further, the ACD is dependent on the accommodative state of the lens, i.e., whether the lens 240 is focusing on an object that is near or far.


The quality of the image that reaches the retina is related to the amount and type of optical aberrations that each patient's eye presents. The ocular surfaces that generally contribute to ocular aberrations are the anterior cornea and the lens. Although, all optical aberrations will affect the quality (e.g. blur) of the image produced on the eye, some aberrations do not necessarily affect the sharpness and the clarity of the object as seen by the patient due to neural compensation. Various embodiments described herein take into account the neural compensation that allows a patient to perceive objects sharply and clearly even in the presence of optical aberrations.


The term “near vision,” as used herein, refers to vision provided by at least a portion of the natural lens in a phakic eye or an intraocular lens in a pseudophakic eye, wherein objects relatively close to a patient are substantially in focus on the retina of the patient's eye. The term “near vision’ generally corresponds to the vision provided when objects are at a distance from the patient's eye of between about 25 cm to about 50 cm. The term “distant vision” or “far vision,” as used herein, refers to vision provided by at least a portion of the natural lens in a phakic eye or an intraocular lens in a pseudophakic eye, wherein objects relatively far from the patient are substantially in focus on the retina of the patient's eye. The term “distant vision” generally corresponds to the vision provided when objects are at a distance of at least about 2 m or greater. As used herein, the “dominant eye” is defined as the eye of the patient that predominates for distant vision, as defined above. The term “intermediate vision,” as used herein, refers to vision provided by at least a portion of the natural lens in a phakic eye or an intraocular lens in a pseudophakic eye, wherein objects at an intermediate distance from the patient are substantially in focus on the retina of the patient's eye. Intermediate vision generally corresponds to vision provided when objects are at a distance of about 2 m to about 50 cm from the patient's eye.


As used herein, an IOL refers to an optical component that is implanted into the eye of a patient. The IOL comprises an optic, or clear portion, for focusing light, and may also include one or more haptics that are attached to the optic and serve to center the optic in the eye between the pupil and the retina along an optical axis. In various implementations, the haptic can couple the optic to zonular fibers of the eye. The optic has an anterior surface and a posterior surface, each having a particular shape that contributes to the refractive properties of the lens.


In the embodiments disclosed herein aberrations and/or additional optical power are provided in a patient's dominant and non-dominant eye to increase depth of focus and to provide improved distant, near and intermediate vision. In some embodiments, rotationally and/or non-rotationally symmetric aberrations can be induced in the patient's dominant and/or non-dominant eye, such that the patient is able to have visual acuity for a wide range of distances. In some embodiments, an optical add power between about +0.5 Diopters and +2.0 Diopters can be provided in addition to inducing rotationally and/or non-rotationally symmetric aberrations. In various embodiments, the optical power and the aberration pattern provided in each eye is selected such that one eye (e.g. the dominant eye) has an extended depth of focus to provide visual acuity at far and intermediate distances and the other eye (e.g. the non-dominant eye) has an extended depth of focus to provide visual acuity at near and intermediate distances. Improved visual acuity at an intermediate distance is obtained due to binocular summation, which is a process by which the brain combines the information it receives from the dominant and the non-dominant eye.


In one aspect, extended depth of focus can be obtained by implanting a first IOL in the first eye and a second IOL in the second eye. The first IOL is selected to have a first optical power and a first optical aberration pattern (e.g. rotationally symmetric or non-rotationally symmetric) to provide visual acuity above a certain threshold for objects located at far to intermediate distances. The second IOL is selected to have a second optical power and a second optical aberration pattern (e.g. rotationally symmetric or non-rotationally symmetric) to provide visual acuity above a certain threshold for objects located at near to intermediate distances. The IOLs can be monofocal or multifocal. In various embodiments, the IOLs can include diffractive features, which may also be rotationally symmetric or asymmetric. The IOLs may also include refractive features, which may also be rotationally symmetric or asymmetric.


In another aspect, extended depth of focus can be obtained by shaping the cornea and/or the lens of the first eye to have a first optical power and a first optical aberration pattern (e.g. rotationally symmetric or non-rotationally symmetric) to provide visual acuity above a certain threshold for objects located at far to intermediate distances; and shaping the cornea and/or the lens of the second eye to have a second optical power and a second optical aberration pattern (e.g. rotationally symmetric or non-rotationally symmetric) to provide visual acuity above a certain threshold for objects located at near to intermediate distances. The shaping of the cornea or the natural lens can be performed by known methods, such as, for example using picosecond or femtosecond laser. Laser ablation procedures can remove a targeted amount stroma of a cornea to change a cornea's contour and adjust for aberrations. In known systems, a laser beam often comprises a series of discrete pulses of laser light energy, with a total shape and amount of tissue removed being determined by a shape, size, location, and/or number of laser energy pulses impinging on a cornea. In an alternative embodiment, the treatment may combine laser and cataract surgery. While during cataract surgery, IOLs implanted may be generating the desired configuration of added powers, with either refractive or diffractive concepts, the combination of rotationally symmetric and non-rotationally symmetric aberrations may be created in a posterior laser treatment that may be applied either in the corneal or in these implanted IOLs. In some embodiments, extended depth of focus can be provided by designing a first lens for use in a first eye, and a second lens for use in a second eye. The first and the second lens can be corneal implants, contact lenses or lenses for use in spectacles. The first and second lenses can be monofocal or multifocal. The first lens has an optical power and an optical aberration pattern that provides distant to intermediate vision. The second lens has an optical power and an optical aberration pattern that provides near to intermediate vision.


In various embodiments described herein rotationally symmetric aberrations (e.g. fourth and higher order spherical aberration terms) are induced in one eye while non-rotationally symmetric aberrations (e.g. astigmatism, coma and trefoil or combination thereof) are induced in the other eye to provide extended depth of focus. In various embodiments, the rotationally symmetric and non-rotationally symmetric aberrations can be superimposed over the naturally occurring aberrations in the eye. In some embodiments, the naturally occurring aberrations in the patient's eye may be corrected or scaled, as detailed in U.S. patent application Ser. No. 13,690,505 referenced above, in addition to inducing the rotationally symmetric or non-rotationally symmetric aberrations.


Rotationally symmetric aberrations, such as, for example including higher order spherical aberration terms can generate a uniform blur. In some instances, this uniform blur can translate into rotationally symmetric halos. On the other hand, non-rotationally symmetric aberrations can generate asymmetric halos which may be more tolerable as compared to rotationally symmetric halos. Providing rotationally symmetric aberrations in one eye and non-rotationally symmetric aberrations in the other eye can advantageously improve intermediate vision and extend depth of focus while reducing the impairments caused by rotationally symmetric halos. In some instances, combining spherical and/or non-rotationally symmetric with monovision can also improve stereopsis, which is related to depth perception.


The amount and type of rotationally symmetric and non-rotationally symmetric aberrations to be induced in each eye can be tested. A visual simulator was used to study whether the amount of aberrations that can be induced to produce a loss of one line in visual acuity is constant through the population. In order to do that, the monocular visual acuity of 5 subjects was measured under cyclopegic conditions when natural aberrations were corrected and those corresponding with an average pseudophakic eye were induced (0.15 μm RMS for a 5 mm pupil). Then, the amount of either spherical aberration or positive vertical coma that produced a loss of visual acuity of 0.1 Log MAR was determined when a physical pupil of 4 mm was imposed. The threshold value for negative SA was the smallest (−0.16±0.04 μm at 5 mm pupil induction), followed by positive SA (0.25±0.05 μm). The custom threshold for VC was consistently the highest (0.78±0.12 μm), ranging from 0.70 to 0.98 μms. Therefore, it is safe to consider a threshold of vertical coma and spherical aberration of about 0.8 μm and 0.2 μm, respectively. Those are the values that may be imposed as rotationally symmetric (spherical aberration) and asymmetric (vertical coma), while possibly correcting natural aberrations and inducing those corresponding to the average pseudophakic eye. This application is particularly advantageous for these eyes with a dense cataract which may increase the difficulty of determining potential customized thresholds.


In another embodiment, the vision simulator can be used to individually determine these monocular thresholds to both rotationally and non rotationally symmetric aberrations. As described previously, the visual acuity can be measured at best focus for a certain pupil size (e.g. 3 mm pupil size, 4 mm pupil size, or 5 mm pupil size). Then, the letter size may be increased until the target visual acuity is reached (ie. that corresponding to the measured VA plus n*0.1 log MAR, being n is a number between 0 and 3). Different values of rotationally symmetric aberrations (e.g. higher order spherical aberrations) or non-rotationally symmetric aberrations (e.g. astigmatism, coma or trefoil) are applied to the eye and the threshold value of rotationally symmetric aberrations and non-rotationally symmetric aberrations is determined as the maximum amount of aberration that allows for resolving that letter size, and therefore, provides with measured VA plus n*0.1 log MAR. Once the monocular thresholds are determined for each eye, the corresponding values are presented binocularly to the subject. In one implementation, the binocular threshold values are the value of the rotationally/non-rotationally symmetric aberration that provides the best through focus as well as comfort for the patient. In some instances, an optical add power (e.g. between about +0.5 Diopters and +3.0 Diopters) can be provided to the non-domination and/or the dominant eye. In an alternative embodiment, rotationally symmetric and asymmetric diffractive designs can also be induced, for the patient to compare between different options.


Another example method 2000 for determining the amount and type of rotationally symmetric and non-rotationally symmetric aberrations to be induced in each eye is illustrated in FIG. 2A. The method includes: (i) determining with a binocular vision simulator a first maximum amount of rotationally symmetric or non-rotationally symmetric aberration which provides distant vision in a first eye, as shown in block 2005; (ii) determining with the binocular vision simulator a second maximum amount of rotationally symmetric or non-rotationally symmetric aberration which provides near vision in a second eye, as shown in block 2010; (iii) applying the first maximum amount of rotationally symmetric or non-rotationally symmetric aberration in the first eye, as shown in block 2015; and (iv) applying the second maximum amount of non-rotationally symmetric or rotationally symmetric aberration in the second eye, as shown in block 2020. In various embodiments, a rotationally symmetric aberration pattern is applied to the second eye if a non-rotationally symmetric aberration pattern is applied in the first eye and vice-versa.


In one implementation of the method 2000 described above, the maximum amount of rotationally symmetric or non-rotationally symmetric aberration is that value selected from all possible values of rotationally symmetric or non-rotationally symmetric aberration which provides the highest extended depth of focus monocularly and the highest visual acuity at an intermediate distance binocularly. As previously discussed, the method 2000 can be implemented with IOLs, corneal implants, contact lenses, lenses for use in spectacles, etc. Alternately, the cornea or the lens of the patient can be shaped in accordance with the method 2000 such that rotationally/non-rotationally symmetric aberrations and an add power are induced in one eye to achieve distant vision with an extended depth of focus; and rotationally/non-rotationally symmetric aberrations and an add power are induced in the other eye to achieve near vision with an extended depth of focus.


An example of the procedure is shown at FIG. 2B, in which spherical aberration represents rotationally symmetric aberration term and vertical coma the non-rotationally symmetric aberration term. In order to select the treatment, the thresholds may be customized, while using a visual simulator as previously described or can be taken from those measured in the average population. Once the thresholds have been determined monocularly, the binocular test starts. Different options are shown in FIG. 2B. For a determined letter size, corresponding to a VA between 0 and 0.1 Log MAR, different viewing distances (0 D of defocus, corresponding to far, −1.5 D of defocus corresponding to intermediate and −2.5 D of defocus corresponding to far) may be shown to a subject for him/her to subjectively judge the option that is more suitable or comfortable. This test can be performed before cataract surgery, in order to make a customized selection of the lens to implant for the patient and only if the degree of cataract allows for visual simulation. The test can be also performed after the surgery, when the resulting aberration patterns or added powers may be induced as a laser treatment either in the cornea or the IOL itself. FIG. 2B lists potential binocular combinations with the first combinations utilizing a purely refractive (mixed monovision) platform. Symmetric diffractive platforms in combination with asymmetric diffractive platforms as seen, for example, in FIGS. 4A1-4A5 may also be used. Symmetric refractive platforms along with asymmetric refractive platforms, such as seen in U.S. patent application Ser. No. 13/309,314, entitled filed on Dec. 1, 2011, and incorporated herein by reference in its entirety, may also be used.


The IOLs or other ophthalmic devices discussed for use herein may be constructed of any commonly employed material or materials used for rigid optics, such as polymethylmethacrylate (PMMA), or of any commonly used materials for resiliently deformable or foldable optics, such as silicone polymeric materials, acrylic polymeric materials, hydrogel-forming polymeric materials, such as polyhydroxyethylmethacrylate, polyphosphazenes, polyurethanes, and mixtures thereof and the like. The material used preferably forms an optically clear optic and exhibits biocompatibility in the environment of the eye. Additionally, foldable/deformable materials are particularly advantageous for formation of implantable ones of ophthalmic lenses for use in the present invention, in part because lenses made from such deformable materials may be rolled, folded or otherwise deformed and inserted into the eye through a small incision.


In addition to providing visual acuity at near, intermediate and far distances, the ophthalmic solutions (e.g. IOLs, contact lenses, corneal implants, etc.) used herein can correct for other conditions of the eye. For example, the ophthalmic solution can be a toric lens for correcting astigmatism and include rotationally/non-rotationally symmetric aberrations to provide enhanced visual acuity. As another example, the ophthalmic solution can be an aspheric lens including rotationally/non-rotationally symmetric aberrations to provide enhanced visual acuity. As yet another example, the ophthalmic solution can be a combination of refractive and diffractive features that are rotationally/non-rotationally symmetric to provide enhanced visual acuity.


The methods described herein can be performed by using instruments that are known to a person having ordinary skill in the art. An instrument to implement the methods described herein can comprise a set of apparatuses, including a set of apparatuses from different manufacturers that are configured to perform the necessary measurements and calculations. Any instrument comprising all needed measurements (ocular and corneal wavefront aberration measurements) as well as the needed calculations to implement the methods described herein, including but not limited to the method 2000 can be considered as an inventive embodiment. FIG. 3 is a block diagram illustrating an embodiment of a clinical system 3000 that can be used to implement the methods described herein, including but not limited to the method 2000. The system 3000 includes one or more apparatuses capable of performing the calculations, assessments and comparisons set forth in determining the rotationally/non-rotationally symmetric aberration patterns and the add power that provide enhanced visual acuity at near, intermediate and far distances. The system 3000 may include a biometric reader 3001 (e.g. a binocular vision simulator), a processor 3002, and a computer readable memory or medium 3004 coupled to the processor 3002. The computer readable memory 3004 includes therein an array of ordered values 3008 and sequences of instructions 3010 which, when executed by the processor 3002, cause the processor 3002 to select the rotationally/non-rotationally symmetric aberration pattern that provides distant vision with an extended depth of focus in one eye and near vision with an extended depth of focus in the other eye such that an enhanced visual acuity at an intermediate distance is obtained by binocular summation.


The array of ordered values 3008 can include one or more desired refractive outcomes, data obtained from measurements of the patient's eye, data related to one or more types of available ophthalmic solutions, a set of all possible rotationally/non-rotationally symmetric aberration patterns, parameters of refractive and diffractive features, etc. In some embodiments, the sequence of instructions 3010 can include algorithms to perform calculations, customization, simulation, comparison, etc.


The processor 3002 may be embodied in a general purpose desktop, laptop, tablet or mobile computer, and/or may comprise hardware and/or software associated with inputs 3001. In certain embodiments, the system 3000 may be configured to be electronically coupled to another device, such as one or more instruments for obtaining measurements of an eye or a plurality of eyes. Alternatively, the system 3000 may be adapted to be electronically and/or wirelessly coupled to one or more other devices.


The system illustrated in FIG. 3 can be used for selecting the rotationally/non-rotationally symmetric optical aberration patterns in blocks 2005 and 2010 of the method 2000. For example, the clinical measurements provided by the reader 3001, can be used to determine which rotationally/non-rotationally symmetric optical treatments stored in the processor 3002 provides distant vision with an extended depth of focus in one eye and near vision with an extended depth of focus in the other eye such that an enhanced visual acuity at an intermediate distance is obtained by binocular summation.


As discussed above, the methods described herein can be implemented in lenses (e.g. IOLs, contact lenses, lenses for use with spectacles, etc.). For example, in some embodiments, the lenses can be monofocal lenses that provide distant or near vision that include rotationally/non-rotationally symmetric aberration pattern for providing visual acuity for object located at intermediate distance. As another example, in some embodiments, the lenses can be multifocal lenses providing distant and near vision and further including rotationally/non-rotationally symmetric aberration pattern for providing visual acuity for object located at intermediate distance. As yet another example, in some embodiments, the lenses can have refractive or diffractive features that are symmetric or asymmetric such that improved visual acuity at near, intermediate and far distances is obtained. Some examples of lenses including rotationally asymmetric features that provide improved visual acuity at near, intermediate and far distances are discussed below with reference to FIGS. 4A1-4A5. As discussed above, rotationally symmetric aberrations can include higher order (e.g. 4th and 6th order) spherical aberrations. As discussed above, non-rotationally symmetric aberrations can include astigmatism, coma or trefoil.


By way of example, FIGS. 4A1-4A5 shows various embodiments of lenses including rotationally asymmetric diffractive features. The lenses illustrated in FIGS. 4A1-4A5 include a plurality of partially annular structures. The partially annular structures can be distributed around a central optical zone disposed about an optical axis. In some embodiments, the optical zone between two consecutive partially annular structures can have an optical power that is equal to the optical power of the central zone. In some other embodiments, the optical zone between two consecutive partially annular structures can have an optical power that is different from the optical power of the central zone. Each of the partially annular structure can include microstructures that are diffractive or refractive. Each of the partially annular structure can have a vertical and horizontal profile that determines the overall optical power of the lens and the distribution of light between the various optical zones.


In FIG. 4A1, region A1 includes a plurality of semi-annular structures that cover about 50% of the surface area of the ophthalmic lens. The upper part of the lens has 50% light distribution between 1 D and 2D add power, while the rest has an asymmetric light distribution between the same add powers. In various embodiments, the portion of the ophthalmic lens below the region A1 can be devoid of microstructures or include microstructures similar to the microstructures in the region A1, such that the ophthalmic lens illustrated in FIG. 4A1 is rotationally symmetric. In an alternative embodiment, the lower part may be composed by a different diffractive designs which provides different add powers and light distributions.


FIG. 4A2 illustrates an ophthalmic lens including a first region A2 having partially annular structures with an add power of 1 D, being essentially monofocal, and a second region B2 having partially annular structures with an add power of 2D, also monofocal. The regions A2 and B2 can each occupy about 25% of the surface area of the ophthalmic lens, while the remaining approximately 50% of the lens has a 0 D add power and its basically refractive monofocal.


FIG. 4A3 illustrates an ophthalmic lens including a first region A3 having partially annular structures with an add power of 2D, being essentially monofocal, a second region B3 having partially annular structures with an add power of 3D, being essentially monofocal, and a third region C3 having partially annular structures with an add power of 1 D, being essentially monofocal. The regions A3 and B3 can each occupy about 25% of the surface area of the ophthalmic lens and the region C3 can occupy about 50% of the surface area of the ophthalmic lens. The area occupied by every different sector can be modified as shown in FIG. 4A4, where each region subtends the same area. In an alternative embodiment, at FIG. 4A5, the area occupied by the region with an add power of 1 D is greater than for the rest.


Although the invention has been described and pictured in an exemplary form with a certain degree of particularity, it should be understood that the present disclosure of the exemplary form has been made by way of example, and that numerous changes in the details of construction and combination and arrangement of parts and steps may be made without departing from the spirit and scope of the invention as set forth in the claims hereinafter.

Claims
  • 1. A pair of intraocular lenses comprising: a first intraocular lens sized and configured for implantation in a first eye of a patient, the first intraocular lens including rotationally symmetric aberrations configured to induce a predetermined amount of spherical aberrations in the first eye of the patient; anda second intraocular lens sized and configured for implantation in a second eye of the patient, the second intraocular lens including non-rotationally symmetric aberrations configured to induce a predetermined amount of asymmetrical aberrations in the second eye of the patient;wherein the combination of the predetermined amount of spherical aberrations and the predetermined amount of asymmetrical aberrations cooperate to improve intermediate vision when implanted in the eyes of the patient.
  • 2. The pair of lenses of claim 1, wherein the predetermined amount of spherical aberrations is induced only in the first eye of the patient, and the predetermined amount of asymmetrical aberrations is induced only in the second eye of the patient.
  • 3. The pair of lenses of claim 1, wherein the non-rotationally symmetric aberrations are selected from the group consisting of: astigmatism, coma and trefoil.
  • 4. The pair of lenses of claim 1, wherein the first intraocular lens is configured to provide visual acuity above a predetermined threshold for objects located at far and intermediate distances or far and near distances and the second intraocular lens is configured to provide visual acuity above a predetermined threshold for objects located at far distances.
  • 5. The pair of lenses of claim 1, wherein the rotationally symmetric aberrations are configured to induce a predetermined amount of one or more fourth or higher order spherical aberrations in the first eye of the patient.
  • 6. The pair of lenses of claim 5, wherein the non-rotationally symmetric aberrations are configured to induce a predetermined amount of one or more second or higher order asymmetrical aberrations in the second eye of the patient.
  • 7. The pair of lenses of claim 1, wherein the combination of the predetermined amount of spherical aberrations and the predetermined amount of asymmetrical aberrations collectively achieve binocular depth of focus.
  • 8. The pair of lenses of claim 1, wherein at least one of the first intraocular lens or the second intraocular lens provides an optical add power.
  • 9. The pair of lenses of claim 1, wherein the first intraocular lens has an extended depth of focus to provide visual acuity at far and intermediate distances.
  • 10. The pair of lenses of claim 9, wherein the second intraocular lens has an extended depth of focus to provide visual acuity at near and intermediate distances.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to and is a divisional of U.S. patent application Ser. No. 15/665,109, filed Jul. 31, 2017, which is a divisional of U.S. patent application Ser. No. 14/096,544, filed on Dec. 4, 2013, now U.S. Pat. No. 9,717,628, which claims priority to U.S. provisional application No. 61/733,292 filed on Dec. 4, 2012, the entire contents of which are incorporated herein by reference.

US Referenced Citations (254)
Number Name Date Kind
2077092 Broder Apr 1937 A
3305294 Alvarez Feb 1967 A
3367734 Karl et al. Feb 1968 A
3735685 Plummer May 1973 A
4010496 Neefe Mar 1977 A
4077071 Freeman Mar 1978 A
4093361 Erickson et al. Jun 1978 A
4134160 Bayers Jan 1979 A
4162122 Cohen Jul 1979 A
4174543 Kelman Nov 1979 A
4210391 Cohen et al. Jul 1980 A
4249272 Poler Feb 1981 A
4254509 Tennant Mar 1981 A
4254510 Tennant Mar 1981 A
4316293 Bayers Feb 1982 A
4319564 Karickhoff Mar 1982 A
4338005 Cohen Jul 1982 A
4340283 Cohen Jul 1982 A
4370760 Kelman Feb 1983 A
4377873 Reichert, Jr. Mar 1983 A
4402579 Poler Sep 1983 A
4403353 Tennant Sep 1983 A
4404694 Kelman Sep 1983 A
4409691 Levy Oct 1983 A
4424597 Schlegel Jan 1984 A
4446581 Blake May 1984 A
4480340 Shepard Nov 1984 A
4500382 Foster Feb 1985 A
4504982 Burk Mar 1985 A
4551864 Akhavi Nov 1985 A
4556998 Siepser Dec 1985 A
4560383 Leiske Dec 1985 A
4593981 Scilipoti Jun 1986 A
4605409 Kelman Aug 1986 A
4605411 Fedorov et al. Aug 1986 A
4629460 Dyer Dec 1986 A
4629462 Feaster Dec 1986 A
4636049 Blaker Jan 1987 A
4637697 Freeman Jan 1987 A
4642112 Freeman Feb 1987 A
4655565 Freeman Apr 1987 A
4673406 Schlegel Jun 1987 A
4676791 Lemaster et al. Jun 1987 A
4676792 Praeger Jun 1987 A
4681102 Bartell Jul 1987 A
4687484 Kaplan Aug 1987 A
4687485 Lim et al. Aug 1987 A
RE32525 Pannu Oct 1987 E
4725277 Bissonette Feb 1988 A
4734095 Siepser Mar 1988 A
4778462 Grendahl Oct 1988 A
4781717 Grendahl Nov 1988 A
4787903 Grendahl Nov 1988 A
4787904 Severin et al. Nov 1988 A
4795462 Grendahl Jan 1989 A
4798608 Grendahl Jan 1989 A
4798609 Grendahl Jan 1989 A
4828558 Kelman May 1989 A
4834748 Mcdonald May 1989 A
4863539 Lee et al. Sep 1989 A
4898461 Portney Feb 1990 A
4932970 Portney Jun 1990 A
4995714 Cohen Feb 1991 A
4995715 Cohen Feb 1991 A
4997442 Barrett Mar 1991 A
5016977 Baude et al. May 1991 A
5019097 Knight et al. May 1991 A
5047052 Dubroff Sep 1991 A
5054905 Cohen Oct 1991 A
5056908 Cohen Oct 1991 A
5066301 Wiley Nov 1991 A
5071432 Baikoff Dec 1991 A
5078742 Dahan Jan 1992 A
5089023 Swanson Feb 1992 A
5096285 Silberman Mar 1992 A
5114220 Baude et al. May 1992 A
5117306 Cohen May 1992 A
5120120 Cohen Jun 1992 A
5121979 Cohen Jun 1992 A
5121980 Cohen Jun 1992 A
5133749 Nordan Jul 1992 A
5144483 Cohen Sep 1992 A
5147395 Willis Sep 1992 A
5147397 Christ et al. Sep 1992 A
5184405 Cress Feb 1993 A
5197981 Southard Mar 1993 A
5201763 Brady et al. Apr 1993 A
5203790 Mcdonald Apr 1993 A
5217491 Vanderbilt Jun 1993 A
5225858 Portney Jul 1993 A
5225997 Lederer et al. Jul 1993 A
5229797 Futhey et al. Jul 1993 A
5258025 Fedorov et al. Nov 1993 A
5278592 Marie et al. Jan 1994 A
5408281 Zhang Apr 1995 A
5433745 Graham et al. Jul 1995 A
5476513 Brady et al. Dec 1995 A
5479220 Komatsu et al. Dec 1995 A
5567365 Weinschenk, III et al. Oct 1996 A
5571177 Deacon et al. Nov 1996 A
5620720 Glick et al. Apr 1997 A
5628796 Suzuki May 1997 A
5652638 Roffman et al. Jul 1997 A
5691800 Iki et al. Nov 1997 A
5699142 Lee et al. Dec 1997 A
5715031 Roffman et al. Feb 1998 A
5716403 Tran et al. Feb 1998 A
5748282 Freeman May 1998 A
5760871 Kosoburd et al. Jun 1998 A
5796462 Roffman et al. Aug 1998 A
5801807 Satake et al. Sep 1998 A
5928282 Nigam Jul 1999 A
5968094 Werblin et al. Oct 1999 A
6015435 Valunin et al. Jan 2000 A
6051024 Cumming Apr 2000 A
6055111 Nomura et al. Apr 2000 A
6126283 Wen et al. Oct 2000 A
6126286 Portney Oct 2000 A
6129759 Chambers Oct 2000 A
6142625 Sawano et al. Nov 2000 A
6179870 Sourdille et al. Jan 2001 B1
6210005 Portney Apr 2001 B1
6235055 Chu May 2001 B1
6261321 Kellan Jul 2001 B1
6319282 Nishi Nov 2001 B1
6338559 Williams et al. Jan 2002 B1
6419697 Kelman Jul 2002 B1
6457826 Lett Oct 2002 B1
6464355 Gil Oct 2002 B1
6474814 Griffin Nov 2002 B1
6488708 Sarfarazi Dec 2002 B2
6491721 Freeman et al. Dec 2002 B2
6527389 Portney Mar 2003 B2
6533416 Fermigier et al. Mar 2003 B1
6536899 Fiala Mar 2003 B1
6537317 Steinert et al. Mar 2003 B1
6547822 Lang Apr 2003 B1
6554859 Lang et al. Apr 2003 B1
6557992 Dwyer et al. May 2003 B1
6598606 Terwee et al. Jul 2003 B2
6609793 Norrby et al. Aug 2003 B2
6705729 Piers et al. Mar 2004 B2
6709102 Duppstadt Mar 2004 B2
6802605 Cox et al. Oct 2004 B2
6808262 Chapoy et al. Oct 2004 B2
6830332 Piers et al. Dec 2004 B2
6846326 Zadno-Azizi et al. Jan 2005 B2
6851803 Wooley et al. Feb 2005 B2
6899425 Roffman et al. May 2005 B2
6923539 Simpson et al. Aug 2005 B2
6923540 Ye et al. Aug 2005 B2
6986578 Jones Jan 2006 B2
7036931 Lindacher et al. May 2006 B2
7048760 Cumming May 2006 B2
7061693 Zalevsky Jun 2006 B2
7073906 Portney Jul 2006 B1
7137702 Piers et al. Nov 2006 B2
7156516 Morris et al. Jan 2007 B2
7188949 Bandhauer et al. Mar 2007 B2
7287852 Fiala Oct 2007 B2
7293873 Dai et al. Nov 2007 B2
7365917 Zalevsky Apr 2008 B2
7377640 Piers et al. May 2008 B2
7441894 Zhang et al. Oct 2008 B2
7455404 Bandhauer et al. Nov 2008 B2
7455407 Neal et al. Nov 2008 B2
7475986 Dai et al. Jan 2009 B2
7615073 Deacon et al. Nov 2009 B2
7616330 Neal et al. Nov 2009 B2
7713299 Brady et al. May 2010 B2
7794497 Brady et al. Sep 2010 B2
7857451 Thibos et al. Dec 2010 B2
7871162 Weeber Jan 2011 B2
7993398 Deacon et al. Aug 2011 B2
8002827 Deacon et al. Aug 2011 B2
8018164 Shannon et al. Sep 2011 B2
8231219 Weeber Jul 2012 B2
8241354 Hong et al. Aug 2012 B2
8382281 Weeber Feb 2013 B2
8430508 Weeber Apr 2013 B2
8480228 Weeber Jul 2013 B2
8573775 Weeber Nov 2013 B2
8747466 Weeber et al. Jun 2014 B2
8770745 Lindacher et al. Jul 2014 B2
8862447 Weeber Oct 2014 B2
9335563 Weeber May 2016 B2
20010035935 Bhalakia et al. Nov 2001 A1
20010051825 Peterson Dec 2001 A1
20020118337 Perrott et al. Aug 2002 A1
20020173846 Blake et al. Nov 2002 A1
20020196408 Bhalakia et al. Dec 2002 A1
20020196412 Abitbol Dec 2002 A1
20030076478 Cox Apr 2003 A1
20030171808 Phillips Sep 2003 A1
20040054358 Cox et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040085515 Roffman et al. May 2004 A1
20040106992 Lang et al. Jun 2004 A1
20040111153 Woods et al. Jun 2004 A1
20040150790 Roffman et al. Aug 2004 A1
20040156014 Piers et al. Aug 2004 A1
20040167622 Sunalp et al. Aug 2004 A1
20050096226 Stock et al. May 2005 A1
20050125056 Deacon et al. Jun 2005 A1
20050128432 Altmann Jun 2005 A1
20050203619 Altmann Sep 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060009816 Fang et al. Jan 2006 A1
20060030938 Altmann Feb 2006 A1
20060066808 Blum et al. Mar 2006 A1
20060068453 Altieri Mar 2006 A1
20060109421 Ye et al. May 2006 A1
20060116763 Simpson Jun 2006 A1
20060116764 Simpson Jun 2006 A1
20060116765 Blake et al. Jun 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060244904 Hong et al. Nov 2006 A1
20060244916 Guillon Nov 2006 A1
20060279700 Liang Dec 2006 A1
20070052920 Stewart et al. Mar 2007 A1
20070129803 Cumming et al. Jun 2007 A1
20070171362 Simpson et al. Jul 2007 A1
20070182924 Hong et al. Aug 2007 A1
20070268453 Hong et al. Nov 2007 A1
20070279585 Bartoli Dec 2007 A1
20080018910 Neal et al. Jan 2008 A1
20080030677 Simpson Feb 2008 A1
20080161914 Brady et al. Jul 2008 A1
20080231809 Haigis Sep 2008 A1
20080273169 Blum et al. Nov 2008 A1
20080291393 Menezes Nov 2008 A1
20090012609 Geraghty et al. Jan 2009 A1
20090036980 Norrby et al. Feb 2009 A1
20090051876 Seiler et al. Feb 2009 A1
20090062911 Bogaert Mar 2009 A1
20090088840 Simpson et al. Apr 2009 A1
20090164008 Hong et al. Jun 2009 A1
20090210054 Weeber et al. Aug 2009 A1
20090234448 Weeber et al. Sep 2009 A1
20090279048 Hong et al. Nov 2009 A1
20090295295 Shannon et al. Dec 2009 A1
20090323020 Zhao et al. Dec 2009 A1
20100016965 Hong et al. Jan 2010 A1
20100082017 Zickler et al. Apr 2010 A1
20100100178 Weeber et al. Apr 2010 A1
20100161048 Schaper, Jr. Jun 2010 A1
20100274234 Liang Oct 2010 A1
20120078239 Reinstein et al. Mar 2012 A1
20120123534 Yoon et al. May 2012 A1
20120140166 Zhao Jun 2012 A1
20120143326 Canovas et al. Jun 2012 A1
20120320334 Ho et al. Dec 2012 A1
20130335701 Canovas et al. Dec 2013 A1
Foreign Referenced Citations (57)
Number Date Country
2722274 Oct 2009 CA
1035363 Sep 1989 CN
1039487 Feb 1990 CN
1406120 Mar 2003 CN
1833192 Sep 2006 CN
8107675 Jul 1981 DE
226400 Jun 1987 EP
227357 Jul 1987 EP
0343067 Nov 1989 EP
0457553 Nov 1991 EP
681198 Nov 1995 EP
0926531 Jun 1999 EP
949529 Oct 1999 EP
957331 Nov 1999 EP
1424049 Jun 2004 EP
1310267 Jan 2008 EP
1424049 Jun 2009 EP
2182891 Apr 2014 EP
2745711 Sep 1997 FR
H0255314 Feb 1990 JP
8603961 Jul 1986 WO
9222264 Dec 1992 WO
9303409 Feb 1993 WO
9507487 Mar 1995 WO
9856315 Dec 1998 WO
0019906 Apr 2000 WO
0111418 Feb 2001 WO
0135868 May 2001 WO
0154569 Aug 2001 WO
0163344 Aug 2001 WO
0182839 Nov 2001 WO
0189424 Nov 2001 WO
0221194 Mar 2002 WO
03009053 Jan 2003 WO
2004034129 Apr 2004 WO
2004090611 Oct 2004 WO
2004096014 Nov 2004 WO
05019906 Mar 2005 WO
06025726 Mar 2006 WO
2006032263 Mar 2006 WO
2006047698 May 2006 WO
06060477 Jun 2006 WO
2006060480 Jun 2006 WO
2007067872 Jun 2007 WO
2007092948 Aug 2007 WO
2007133384 Nov 2007 WO
2008045847 Apr 2008 WO
2008083283 Jul 2008 WO
2009020963 Feb 2009 WO
2009029515 Mar 2009 WO
2009058755 May 2009 WO
2009076670 Jun 2009 WO
2009137491 Nov 2009 WO
2010009254 Jan 2010 WO
2010009257 Jan 2010 WO
2011028659 Mar 2011 WO
2013080053 Jun 2013 WO
Non-Patent Literature Citations (37)
Entry
Alfonso J.F., et al., “Prospective Study of the Acri.LISA Bifocal Intraocular Lens,” Journal of Cataract Refractive Surgery, Nov. 2007, vol. 33 (11), pp. 1930-1935.
Alio J.L., et al., “Phakic Anterior Chamber Lenses for the Correction of Myopia: A 7-Year Cumulative Analysis of Complications in 263 Cases,” Ophthalmology, Mar. 1999, vol. 106 (3), pp. 458-466.
Apple D.J., et al., “Anterior Chamber Lenses Part 1: Complications and Pathology and a Review of Designs,” Journal of Cataract Refractive Surgery, Mar. 1987, vol. 13 (2), pp. 157-174.
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 22 (36), pp. 205-221.
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 36 (1), pp. 21-36.
Baikoff G., et al., “Angle-fixated Anterior Chamber Phakic Intraocular Lens for Myopia 7 to -19 Diopters,” Journal of Refractive Surgery, May-Jun. 1998, vol. 14 (3), pp. 282-292.
Canovas C., et al., “Hybrid Adaptive-Optics Visual Simulator,” Optical Letters, Jan. 15, 2010, vol. 35 (2), pp. 196-198.
Cheng X., et al., “Predicting Subjective Judgment of Best Focus with Objective Image Quality Metrics,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 310-321.
CILCO Advertisement Brochure, Oct. 1982, 3 pages.
Cohen A.L., “Practical Design of a Bifocal Hologram Contact Lens or Intraocular Lens,” Applied Optics, Jul. 1, 1992, vol. 31 (19), pp. 3750-3754.
De Almeida M.S., et al., “Different Schematic Eyes and their Accuracy to the in Vivo Eye: A Quantitative Comparison Study,” Brazilian Journal of Physics, Jun. 2007, vol. 37 (2A), 10 pages.
Diffractive Lenses for Extended Depth of Focus and Presbyopic Correction, Presentation from Wavefront Congress held on Feb. 15, 2008, Rochester, New York.
Doskolovich L.L., et al., “Special Diffractive Lenses,” Lens and Optical Systems Design, Apr. 1992, vol. 1780, pp. 393-402.
Kim J.H., et al., “The Analysis of Predicted Capsular Bag Diameter using Modified Model of Capsule Measuring Ring in Asians,” Clinical and Experimental Ophthalmology, Apr. 2008, vol. 36 (3), pp. 238-244.
Liou H.L., et al., “Anatomically Accurate, Finite Model Eye for Optical Modeling,” Journal of Optical Society of America, Aug. 1997, vol. 14 (8), pp. 1684-1695.
Liou H.L., et al., “The Prediction of Spherical Aberration with Schematic Eyes,” Ophthalmic and Physiological Optics, Jan. 1996, vol. 16 (4), pp. 348-354.
Marinho A., “Results are Encouraging for Phakic IOLs, but More Work is needed,” Refractive Surgery, Feb. 2000, p. 12, 15.
Marsack J.D., et al., “Metrics of Optical Quality Derived from Wave Aberrations Predict Visual Performance,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 322-328.
Menapace R., “The Capsular Tension Rings,” Journal of Cataract & Refractive Surgery, Dec. 10, 2008, Chap. 3, pp. 27-44.
Monsoriu J.A., et al., “Devil's Lenses,” Optics Express, Oct. 17, 2007, vol. 15 (21), pp. 13858-13864.
Navarro R., et al., “Accommodation-Dependent Model of the Human Eye with Aspherics,” Journal of the Optical Society of America, Aug. 1985, vol. 2 (8), pp. 1273-1281.
Nio Y.K., et al., “Effect of Intraocular Lens Implantation on Visual Acuity, Contrast Sensitivity, and Depth of Focus,” Journal of Cataract and Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2073-2081.
Norrby S., et al., “Model Eyes for Evaluation of Intraocular Lenses,” Applied Optics, Sep. 7, 2007, vol. 46 (26), pp. 6595-6605.
Olsen T., “Simple Method to Calculate the Surgically Induced Refractive Change,” Journal of Cataract & Refractive Surgery, Mar. 1993, vol. 19 (2), pp. 319-320.
Piers P.A., et al., “Eye Models for the Prediction of Contrast Vision in Patients with New Intraocular Lens Designs,” Optics Letters, Apr. 1, 2004, vol. 29 (7), pp. 733-735.
Piers P.A., et al., “Theoretical Comparison of Aberration-Correcting Customized and Aspheric Intraocular Lenses,” Journal of Refractive Surgery, Apr. 2007, vol. 23 (4), pp. 374-384.
Praeger D.L., “Praeger Technique for the Insertion of the Copeland Radial IOL Posterior Chamber Placement,” Copeland Lens, 1982, 7 pages.
Siedlecki D., et al., “Radial Gradient index Intraocular Lens: a Theoretical Model,” Journal of Modern Optics, Feb. 20-Mar. 10, 2008, vol. 55 (4-5), pp. 639-647.
Strenn K., et al., “Capsular bag Shrinkage after Implantation of an Open-Loop Silicone Lens and a Poly(methyl methacrylate) Capsule Tension Ring,” Journal of Cataract and Refractive Surgery, Dec. 1997, vol. 23 (10), pp. 1543-1547.
Tehrani M., et al., “Capsule Measuring Ring to Predict Capsular Bag Diameter and Follow its Course after Foldable Intraocular Lens Implantation,” Journal of Cataract Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2127-2134.
Terwee T., et al., “Visualization of the Retinal Image in an Eye Model With Spherical and Aspheric, Diffractive, and Refractive Multifocal Intraocular Lenses,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 223-232.
Van Den Berg T.J., “Analysis of Intraocular Straylight, Especially in Relation to Age,” Optometry and Vision Science, Feb. 1995, vol. 72 (2), pp. 52-59.
Van Meeteren A., “Calculations on the Optical Modulation Transfer Function of the Human Eye for White Light,” Optica Acta, May 1974, vol. 21 (5), pp. 395-412.
Vass C., et al., “Prediction of Pseudophakic Capsular bag Diameter based on Biometric Variables,” Journal of Cataract and Refractive Surgery, Oct. 1999, vol. 25 (10), pp. 1376-1381.
Venter, J.A., et al., “Visual Outcomes and Patient Satisfaction with a Rotational Asymmetric Refractive Intraocular Lens for Emmetropic Presbyopia,” Cataract & Refractive Surgery, Mar. 2015, vol. 41 (3), pp. 585-593.
Villegas E.A., et al., “Correlation between Optical and Psychophy, Sical Parameters as a Function of Defocus,” Optometry and Vision Science, Jan. 1, 2002, vol. 79 (1), pp. 60-67.
Zheleznyak L., et al., “Modified Monovision to Improve Binocular Through-Focus Visual Performance,” ARVO Meeting Abstracts Apr. 22, 2011, Apr. 4, 2011, [retrieved on May 8, 2013], Retrieved from the Internet.
Related Publications (1)
Number Date Country
20200276051 A1 Sep 2020 US
Provisional Applications (1)
Number Date Country
61733292 Dec 2012 US
Divisions (2)
Number Date Country
Parent 15665109 Jul 2017 US
Child 16875954 US
Parent 14096544 Dec 2013 US
Child 15665109 US